BC Week In Review | Feb 16, 2018
Clinical News

Catabasis reports 60-week data for edasalonexent in DMD

Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) reported that edasalonexent (CAT-1004) preserved muscle function and slowed disease progression through 60 weeks of treatment in an open-label extension of the U.S. Phase I/II MoveDMD trial in steroid-naïve Duchenne muscular...
BC Extra | Feb 13, 2018
Clinical News

Catabasis gains on 60-week DMD data

Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) was up $0.31 (25%) to $1.56 on Tuesday after reporting that edasalonexent (CAT-1004) preserved muscle function and slowed disease progression through 60 weeks of treatment in an open-label extension of the...
BioCentury | Oct 13, 2017
Regulation

Seeking surrogates

Thanks to flaws in PTC Therapeutics Inc. ’s trials, the recent FDA advisory committee meeting to discuss Translarna ataluren did nothing to clarify what level of dystrophin expression would be necessary to support an accelerated...
BC Innovations | Oct 10, 2017
Distillery Therapeutics

Neurology

INDICATION: Ataxia Cell culture studies suggest inhibiting NF-κB could help treat spinocerebellar ataxia type 17 (SCA17), which is caused by CAG/CAA repeat expansions in the TBP gene. In co-cultures of primary neurons and astrocytes from...
BC Week In Review | Oct 6, 2017
Clinical News

Catabasis' DMD candidate slows disease progression in Phase I/II

Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) reported data from the open-label extension of the Phase I/II MoveDMD trial showing that edasalonexent (CAT-1004) slowed disease progression in boys ages 4-7 with Duchenne muscular dystrophy (DMD). The company plans...
BC Extra | Oct 4, 2017
Clinical News

Catabasis reports DMD candidate slowed disease progression

Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) gained $0.20 to $3.03 on Wednesday after it said results from the open-label extension of the Phase II MoveDMD trial showed edasalonexent (CAT-1004) slowed disease progression in boys aged 4-7 with...
BC Week In Review | Sep 1, 2017
Clinical News

Catabasis' edasalonexent misses primary in Phase II for DMD

In April, Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) reported data from the Phase II portion of the U.S. Phase I/II MoveDMD trial in patients ages 4-7 with Duchenne muscular dystrophy (DMD) not on corticosteroids showing that edasalonexent...
BC Week In Review | Oct 3, 2016
Company News

Catabasis Pharmaceuticals, Sarepta Therapeutics deal

The companies partnered to conduct mouse model research to evaluate Duchenne muscular dystrophy (DMD) therapies comprising Sarepta’s exon skipping technology and Exondys 51 eteplirsen analog with Catabasis’ edasalonexent ( CAT-1004 ), a conjugate of salicylate and...
BC Extra | Sep 29, 2016
Company News

Catabasis, Sarepta to study DMD combination

Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) gained $1.77 (40%) to $6.25 Thursday after it partnered with Sarepta Therapeutics Inc. (NASDAQ:SRPT) to study a combination treatment for Duchenne muscular dystrophy. In a mouse model of DMD, the partners...
BC Innovations | Feb 18, 2016
Product R&D

Crossing paths

Selina Koch, Staff Writer  With its first foray into the brain, Catabasis Pharmaceuticals Inc. is using its linker technology to simultaneously target the inflammatory and oxidative stress pathways that drive neurodegeneration, starting with amyotrophic lateral...
Items per page:
1 - 10 of 21